Cargando…
Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders
BACKGROUND: The use of monoclonal antibodies therapy (MAT) in early mild to moderate Coronavirus disease 2019 (COVID-19) has gained importance in recent times. However, there is limited information on the safety and efficacy of MAT in treating COVID-19 in patients with underlying rheumatologic disea...
Autores principales: | Franchin, Giovanni, Mantri, Nikhitha, Zahid, Maleeha, Sun, Haozhe, Gongati, Sudharsan R., Ronderos, Diana M., Gadireddy, Snigdha, Chilimuri, Sridhar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631366/ https://www.ncbi.nlm.nih.gov/pubmed/34819488 http://dx.doi.org/10.12659/MSM.934267 |
Ejemplares similares
-
COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab
por: Chilimuri, Sridhar, et al.
Publicado: (2021) -
BNT162b2 mRNA Vaccine Interference with Co-Administration of Tdap Vaccine
por: Chilimuri, Sridhar, et al.
Publicado: (2021) -
Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: A South-Bronx experience
por: Chilimuri, Sridhar, et al.
Publicado: (2022) -
Potential predictors of outcomes among hospitalized COVID-19 patients treated with convalescent plasma: a single-center study
por: Chilimuri, Sridhar, et al.
Publicado: (2021) -
Impact of Prediabetes and Type-2 Diabetes on Outcomes in Patients with COVID-19
por: Makker, Jasbir, et al.
Publicado: (2021)